Basilea Pharmaceutica AG raised gross proceeds of CHF205.8 million (US$161.2 million) in Europe’s second significant biotechnology initial public offering of 2004. The Basel, Switzerland, drug development company sold 28.5 percent of its equity, or 2.1 million shares, priced at CHF98 per share, having initially set a price range of CHF90 to CHF115.
